- South Korea
- /
- Biotech
- /
- KOSDAQ:A196170
3 KRX Growth Companies With High Insider Ownership Expecting Up To 64% Revenue Growth
Reviewed by Simply Wall St
In the last week, the South Korean market has stayed flat, with notable gains in the Healthcare sector at 5.6%. Despite this overall stability, earnings are forecast to grow by 29% annually, making growth companies with high insider ownership particularly attractive for investors seeking strong revenue potential.
Top 10 Growth Companies With High Insider Ownership In South Korea
Name | Insider Ownership | Earnings Growth |
People & Technology (KOSDAQ:A137400) | 16.4% | 35.6% |
Seojin SystemLtd (KOSDAQ:A178320) | 30.5% | 52.1% |
Bioneer (KOSDAQ:A064550) | 15.8% | 97.6% |
Oscotec (KOSDAQ:A039200) | 26.3% | 122% |
Vuno (KOSDAQ:A338220) | 19.5% | 110.9% |
HANA Micron (KOSDAQ:A067310) | 18.3% | 100.3% |
Park Systems (KOSDAQ:A140860) | 33% | 35.7% |
INTEKPLUS (KOSDAQ:A064290) | 16.3% | 96.7% |
UTI (KOSDAQ:A179900) | 33.1% | 134.6% |
Techwing (KOSDAQ:A089030) | 18.7% | 83.6% |
We'll examine a selection from our screener results.
ALTEOGEN (KOSDAQ:A196170)
Simply Wall St Growth Rating: ★★★★★★
Overview: ALTEOGEN Inc., a bio company with a market cap of ₩18.75 trillion, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars.
Operations: The company's revenue segment primarily comprises biotechnology, generating ₩90.79 billion.
Insider Ownership: 26.6%
Revenue Growth Forecast: 64.2% p.a.
ALTEOGEN, a South Korean biopharmaceutical company, recently received MFDS approval for Tergase®, a high-purity recombinant hyaluronidase. This milestone positions the company as it transitions to commercialization. With earnings forecasted to grow 99.46% annually and revenue expected to increase by 64.2% per year, ALTEOGEN is projected to become profitable in three years with high insider ownership and no recent substantial insider selling. However, shareholders experienced dilution over the past year.
- Unlock comprehensive insights into our analysis of ALTEOGEN stock in this growth report.
- Upon reviewing our latest valuation report, ALTEOGEN's share price might be too optimistic.
Enchem (KOSDAQ:A348370)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Enchem Co., Ltd. manufactures and sells electrolytes and additives for secondary batteries and EDLC, with a market cap of ₩4.17 trillion.
Operations: Enchem's revenue from electronic components and parts is ₩348.75 billion.
Insider Ownership: 19.4%
Revenue Growth Forecast: 63% p.a.
Enchem, a South Korean energy solutions provider, is forecasted to achieve significant revenue growth of 63% annually, outpacing the market. Earnings are expected to grow at 155.2% per year, with profitability anticipated within three years. Despite high insider ownership and no recent substantial insider trading activity, the company has experienced share price volatility and shareholder dilution over the past year.
- Delve into the full analysis future growth report here for a deeper understanding of Enchem.
- The valuation report we've compiled suggests that Enchem's current price could be inflated.
Hyosung Heavy Industries (KOSE:A298040)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Hyosung Heavy Industries Corporation manufactures and sells heavy electrical equipment in South Korea and internationally, with a market cap of ₩3.18 trillion.
Operations: The company's revenue is primarily derived from its Heavy Industry segment, which generated ₩3.35 trillion, and its Construction segment, which brought in ₩1.78 trillion.
Insider Ownership: 16.4%
Revenue Growth Forecast: 10.3% p.a.
Hyosung Heavy Industries, a South Korean industrial firm, is forecasted to achieve significant annual earnings growth of 35.33%, outpacing the market's 29%. Despite trading at 58.7% below its estimated fair value and high insider ownership, revenue growth is expected to be slower than the market at 10.3% per year. The company’s Return on Equity is projected to reach a strong 20.4% in three years, although it faces challenges with high debt not well covered by operating cash flow and recent share price volatility.
- Click here and access our complete growth analysis report to understand the dynamics of Hyosung Heavy Industries.
- Insights from our recent valuation report point to the potential undervaluation of Hyosung Heavy Industries shares in the market.
Seize The Opportunity
- Dive into all 89 of the Fast Growing KRX Companies With High Insider Ownership we have identified here.
- Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
- Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.
Searching for a Fresh Perspective?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About KOSDAQ:A196170
ALTEOGEN
A bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars.
Exceptional growth potential with excellent balance sheet.